Doctors Note Logo

Published on: 1/30/2026

Farxiga Isn’t “Just for Diabetes”—Here’s Why Doctors Prescribe It Now

Farxiga is now used not only for type 2 diabetes, but also for heart failure (HFrEF and HFpEF) and chronic kidney disease, with strong studies showing fewer hospitalizations and cardiovascular deaths and slower kidney decline, even in people without diabetes. There are several factors to consider, including who should not use it and potential side effects like increased urination, genital yeast infections, dehydration, and rare ketoacidosis; see below for key precautions, guideline updates, and the next steps to discuss with your doctor.

answer background

Explanation

Farxiga Isn’t “Just for Diabetes”—Here’s Why Doctors Prescribe It Now

For many years, farxiga was known mainly as a medication for type 2 diabetes. Today, doctors prescribe it for much more than blood sugar control. In fact, farxiga has become an important treatment option for heart failure and chronic kidney disease—even in people who do not have diabetes.

This shift isn’t based on hype or marketing. It’s grounded in strong clinical research and updated medical guidelines. Below, we’ll explain what farxiga is, how it works, why doctors now use it beyond diabetes, and what patients should know before starting it.


What Is Farxiga?

Farxiga (dapagliflozin) is a prescription medication that belongs to a class called SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors).

Originally, farxiga was developed to help people with type 2 diabetes lower blood sugar by helping the kidneys remove excess glucose through urine. Over time, researchers noticed something important: people taking farxiga were also having fewer heart and kidney complications.

That observation changed everything.


How Farxiga Works (In Simple Terms)

Farxiga works primarily in the kidneys. It:

  • Reduces the amount of sugar reabsorbed back into the bloodstream
  • Allows excess glucose to leave the body through urine
  • Lowers blood sugar levels in people with diabetes

But farxiga also has additional effects that help explain its broader use:

  • Reduces pressure inside the kidneys
  • Helps the body get rid of excess salt and fluid
  • Improves how the heart and kidneys use energy

These effects are not limited to people with diabetes—which is why farxiga is now prescribed more widely.


Why Doctors Prescribe Farxiga for More Than Diabetes

1. Heart Failure (With or Without Diabetes)

Farxiga is now approved to treat heart failure, including:

  • Heart failure with reduced ejection fraction (HFrEF)
  • Heart failure with preserved ejection fraction (HFpEF)

Major clinical trials showed that farxiga:

  • Lowers the risk of hospitalization for heart failure
  • Reduces the risk of cardiovascular death
  • Improves symptoms like shortness of breath and fatigue

Importantly, these benefits were seen even in people who do not have diabetes.

Because of this, cardiologists now commonly prescribe farxiga as part of standard heart failure care.


2. Chronic Kidney Disease (CKD)

Farxiga is also approved for chronic kidney disease, including in people without diabetes.

Studies found that farxiga:

  • Slows the progression of kidney damage
  • Reduces the risk of kidney failure
  • Lowers the chance of needing dialysis or a transplant
  • Decreases heart-related complications in people with kidney disease

Kidney specialists often describe farxiga as a “protective” medication—one that helps preserve kidney function over time rather than simply treating symptoms.


3. Type 2 Diabetes (Still a Core Use)

Although farxiga has expanded uses, it remains an important medication for type 2 diabetes.

For diabetes management, farxiga can:

  • Lower A1C (average blood sugar over time)
  • Promote modest weight loss
  • Reduce blood pressure
  • Lower the risk of heart and kidney complications

This combination of benefits makes farxiga especially helpful for people with diabetes who also have heart or kidney concerns.


Why This Matters for People Living With Diabetes

Diabetes affects more than blood sugar. Over time, high glucose levels can damage:

  • Nerves
  • Kidneys
  • Blood vessels
  • The heart

One common complication is diabetic neuropathy, which can cause:

  • Numbness or tingling in the feet or hands
  • Burning or sharp pain
  • Loss of sensation that increases injury risk

If you have diabetes and notice nerve-related symptoms, you might consider doing a free, online symptom check for Diabetic Neuropathy. This kind of tool can help you decide whether it’s time to discuss symptoms with a healthcare professional.


Benefits of Farxiga at a Glance

Doctors often choose farxiga because it offers multiple benefits at once:

  • Helps control blood sugar (in diabetes)
  • Protects kidney function
  • Reduces heart failure hospitalizations
  • Lowers cardiovascular risk
  • Works even in some people without diabetes

This “multi-system” effect is why farxiga has become a cornerstone medication in modern care.


Possible Side Effects and Risks (What to Know)

Farxiga is generally well tolerated, but it’s not risk-free. Common or notable side effects include:

  • Increased urination
  • Genital yeast infections (more common in women, but possible in men)
  • Urinary tract infections
  • Dehydration or low blood pressure, especially in older adults

Less common but serious risks can include:

  • Diabetic ketoacidosis (rare, but possible even with normal blood sugar)
  • Kidney function changes during illness or dehydration

These risks are well known to doctors and are usually manageable with proper monitoring, hydration, and patient education.


Who May Not Be a Good Candidate for Farxiga?

Farxiga may not be appropriate for everyone. Doctors use caution or avoid it in people who:

  • Have type 1 diabetes
  • Have a history of frequent ketoacidosis
  • Have severe kidney failure (below certain function thresholds)
  • Are prone to repeated severe infections

This is why farxiga should only be started under medical supervision.


Why Guidelines Have Changed

Medical organizations focused on diabetes, cardiology, and nephrology now recommend SGLT2 inhibitors like farxiga as first-line or early therapy for many patients with:

  • Type 2 diabetes and heart disease
  • Type 2 diabetes and kidney disease
  • Heart failure, regardless of diabetes status

These recommendations are based on large, well-designed clinical trials published in respected medical journals and reviewed by independent experts.


A Practical Takeaway for Patients

Farxiga is no longer “just a diabetes drug.” It’s a medication that helps protect the heart and kidneys—two organs that are closely connected to long-term health and quality of life.

If you:

  • Have type 2 diabetes
  • Have heart failure
  • Have chronic kidney disease
  • Or have more than one of these conditions

…farxiga may be part of a treatment plan worth discussing.


Talk With a Doctor Before Making Changes

Medication decisions should always be individualized. If you have symptoms that could be serious or life-threatening—such as chest pain, severe shortness of breath, fainting, signs of infection, or sudden changes in urination—you should speak to a doctor right away.

Even for non-urgent concerns, it’s important to talk with a healthcare professional before starting, stopping, or changing any medication, including farxiga.

A thoughtful conversation with your doctor can help you weigh the benefits and risks and decide what’s right for your health now and in the future.

(References)

  • * McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911304. Epub 2019 Sep 15. PMID: 31502758.

  • * Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.

  • * Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 1;387(12):1089-1098. doi: 10.1056/NEJMoa2204791. PMID: 36027734.

  • * Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.

  • * Bergmark BA, et al. SGLT2 Inhibitors for Heart Failure and Kidney Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Mar 7;81(9):895-915. doi: 10.1016/j.jacc.2023.01.009. PMID: 36863777.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Learn more about diseases

Diabetic Neuropathy

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.